Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

August 10, 2022

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging. 

As expressed in the piece, Congress Must Support Innovation, Not Pick Winners and Losers, drug price controls for Medicare sends confusing signals to patients, caregivers, and investors on the importance of medical innovation. 

Confoundingly, it is our Medicare population, the fastest growing segment of patients, that is most dependent on innovation to address diseases from HIV and cancer to osteoporosis and Alzheimer’s.”

Additionally, the legislation itself is peculiarly at odds with the Administration’s renewed Cancer Moonshot initiative, announced as recently as this year’s 2021 State of the Union Address. In that spirit and to ensure limited adverse impact on such future innovation for the health and wellbeing of older adults and all Americans, GCOA and the Alliance for Health Innovation strongly suggest three policy principles accompany any such final legislation that may result in the next days: 

  1. All Medicare “price negotiations” should take place through the screen of its impact on healthy aging & equity. Those administering and overseeing these “price negotiations” must be required to provide to Congress such impact prior to any implementation. Since Medicare will increasingly become a monopsony purchaser as a consequence of the aging of America’s population in our 21st century, the impact will become ever more profound over time and the ensuing responsibilities to show impact ever greater. Healthy aging and equity are impossible without the innovation itself that will enable such patient and caregiver needs. 
  2. HHS & CMS must demonstrate a commitment to transparency & openness in the process for implementing the “Medicare price negotiation” provision. CMS and its parent agency HHS must demonstrate a full commitment to transparency and openness in how it will undertake such a transformational new set of responsibilities. Such transparency is essential so that patients, caregivers, investors, and scientists involved in the biopharmaceutical process across America have a full ability to reflect and communicate the impact it will have on them. CMS has an obligation to ensure open and full dialogue with the ability to partner across society on the impact. 
  3. The legislation should require a report to Congress on the effects of “price negotiations” on innovation, access & equity. Since the prevalence of the diseases of aging increase as 21st-century longevity rises and the fiscal burden grows as the proportion of America’s old outnumbers its young, the economic and fiscal consequences will only be mitigated with a reliable continued flow of new biopharmaceutical innovation. Therefore, any administration of “Medicare price negotiations” must be accompanied by an analysis of the effects on innovation today and in the future. Moreover, such an impact must be done through a full, open, and transparent process that includes society-wide stakeholder input, understood through the lens of equity and healthy aging goals. 

On behalf of GCOA and the Alliance for Health Innovation, we appreciate the ongoing efforts to improve access and affordability for older adults and all Americans and stand ready to work alongside Congress and the Administration to ensure these principles accompany any such final legislation. 

Sincerely,

Michael W. Hodin, PhD 

CEO 

Click here to download PDF of policy statement.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging. 

Ignoring the ‘Silver Economy’ May Be Getting Costly for Brands

In an ad for Airbnb that premiered earlier this year, a couple checks into a cozy Spanish villa. To the tune of Jay-Z's cover of "Me and My Girlfriend," the ad shows the pair settling into their rental and setting their collective dial to chill. They play ping-pong, sip some wine, and get ready for a night on the town. They're also in their 80s, celebrating their 57th wedding anniversary. In no way does the ad characterize the couple as elderly or portray them as needing special aid or services — they are just active people who happen to be old. It's a rare example of ads featuring a realistic depiction of aging.

Health Equity Promise and That Innovation Thing

President Biden has pledged his administration to defeat cancer, Alzheimer’s, and other diseases that target America’s aging population. To achieve these lofty goals, bold words must be backed up by bold actions.

Roundtable Report Highlights Importance of Immunizing Canada’s Caregivers Against Influenza, Identifying Challenges and Opportunities to Protect This Critical Group

The Global Coalition on Aging (GCOA) today released a report summarizing key insights from an expert roundtable on vaccinating Canada’s caregivers against influenza. The roundtable, held virtually, brought together leading Canadian health policy experts, family caregivers, patient advocacy groups, aging experts, and other thought leaders to discuss challenges and strategies to reach this critically important yet hard-to-reach group.